The Lancet Infectious Diseases· Hong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, Shang-Ying Hu, Li Zhang, Kong-Xin Zhu, Kai Chu, Ying Hong, Shu-Fang Chang, Qin-Jing Pan, Xun Zhang, Jin-Bo Xu, Jie Tang, Dong-Ya Yuan, Hui Jiang, Chao Du, Guang Sun, Guo-Hua Zhong, Qi Chen, Li-Hui Wei, You-Lin Qiao, Shao-Wei Li, Ying-Ying Su, Qiu-Fen Zhang, Shou-Jie Huang, Fang-Hui Zhao, Wei-Jin Huang, Ting Wu, Jun Zhang, Ning-Shao Xia·· 2026-07-01AI 评分56
大肠杆菌生产的九价人乳头瘤病毒疫苗三期临床试验结果:有效性、安全性和免疫原性
[Articles] Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial
AI 导读
九价人乳头瘤病毒疫苗在三期临床试验中表现出良好的耐受性、免疫原性和高保护效力,且生产成本低,有望提高全球高价疫苗的可及性。
来源:The Lancet Infectious Diseases · thelancet.com